RxDoctor Payments Data

Valmiki Maharaj, MD

Advanced Heart Failure and Transplant Cardiology · Minneapolis, MNNPI 1215355284

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $26,075 of the $37,643 with a category attached, or 69.3%. Pfizer accounts for 75.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $21,662 and has fallen 95.5% since, to $972 in 2025.

$37,643in general payments, 2019–2025

Across 94 payments — averaging $400.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$28K
  • Abbott$8K
  • Cvrx, Inc.$170
  • Picard Medical Inc.$166
  • Teleflex LLC$132
  • Alnylam Pharmaceuticals Inc.$125
  • plus $531 from 9 others

What the payments were for

  • Speaking & faculty fees$26,07569%
  • Travel & lodging$6,04616%
  • Food & beverage$5,36914%
  • Education$1530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,643 in reported general payments places this provider in the 85th percentile of 32 advanced heart failure and transplant cardiology providers in Minnesota.

See all advanced heart failure and transplant cardiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$62,176
Medicare patients
245
Services billed
818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis177$4,493,868
VyndaqelTafamidis Meglumine18$399,576
JardianceEmpagliflozin282$262,833
EntrestoSacubitril/Valsartan160$181,706
EliquisApixaban86$93,858
FarxigaDapagliflozin Propanediol38$43,426
XareltoRivaroxaban18$27,164
Tacrolimus51$4,372
Mycophenolate Mofetil34$4,296
Eplerenone29$2,791
Isosorbide Dinitrate22$2,231
Potassium Chloride49$2,062
Spironolactone204$1,842
Torsemide45$1,827
GengrafCyclosporine, Modified12$1,479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$28,449$4,987,302281 claims
AstraZenecaFarxiga$92$43,42638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 32 advanced heart failure and transplant cardiology providers in Minnesota.

Other advanced heart failure and transplant cardiology in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →